UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-K/A
 
Amendment No. 1
x                                  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the year ended December 31, 2006
 
OR
o                                    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number 000-51531
 
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-3295878
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification Number)
 
 
341 Oyster Point Boulevard
South San Francisco, California 94080
(Address of principal executive offices, including zip code)
 
(650) 266-3500
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 
  Title of Each Class: 1
 
1 Name of Each Exchange on Which Registered: 1
Common Stock, par value $0.0001 per share
 
The NASDAQ Stock Market, LLC
 
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  o  No  x
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  o  No  x
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x  No  o
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer  o
 
Accelerated filer  x
 
Non-accelerated filer  o
 
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  o  No  x
 
The aggregate market value of common stock held by non-affiliates of the Registrant, based on the last sale price for such stock on June 30, 2006, was $148,602,666.
 
The total number of shares outstanding of the Registrant’s common stock, $0.0001 par value per share, as of March 1, 2007, was 29,459,157.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Portions of the Registrant’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 27, 2007 pursuant to Regulation 14A in connection with the 2007 Annual Meeting of Stockholders of Sunesis Pharmaceuticals, Inc. (hereinafter referred to as “Proxy Statement”) are incorporated by reference in Part III of this report.
 


SUNESIS, INC.
 
ANNUAL REPORT ON FORM 10-K/A
FOR THE YEAR ENDED DECEMBER 31, 2006
 
Explanatory Note to Form 10-K Amendment No. 1
 
This Amendment No. 1 (this “Amendment”) to the Annual Report on Form 10-K for the fiscal year ended December 31, 2006 (the “Form 10-K”) of Sunesis Pharmaceuticals, Inc. is being filed to amend Item 5 of Part II, Item 12 of Part III and Item 15 of Part IV of the Form 10-K and the Exhibit Index to file Exhibits 3.1, 3.2, 10.48, 10.49, 31.1 and 31.2.
 
No other changes have been made to Item 5 of Part II, Item 12 of Part III, Item 15 of Part IV and the Exhibit Index.
 


PART III
 
ITEM 12.          SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
Security Ownership of Certain Beneficial Owners and Management
 
The following table sets forth, as of February 9, 2007, information regarding beneficial ownership of our capital stock by:
 
·        each person, or group of affiliated persons, known by us to beneficially own more than 5% of our voting securities;
 
·        each of our named executive officers;
 
·        each of our directors; and
 
·        all of our executive officers and directors as a group.
 
Beneficial ownership is determined in accordance with the SEC’s rules and generally includes voting or investment power with respect to securities as well as shares of common stock subject to options or warrants exercisable within 60 days of February 9, 2007. Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Sunesis Pharmaceuticals, Inc., 341 Oyster Point Boulevard, South San Francisco, California 94080.
 
Name of Beneficial Owner
 
Shares
Owned (1)
 
Shares Issuable
Pursuant to
Options and
Warrants
Exercisable
Within 60 days of
February 9, 2007
 
Total of
Shares
Beneficially
Owned
 
Percent
 
Named Executive Officers:
                         
Daniel N. Swisher, Jr.
   
32,325
   
359,067
   
391,392
   
1.3
%
Eric H. Bjerkholt
   
2,567
   
122,720
   
125,287
   
*
 
Daniel C. Adelman, M.D.
   
2,658
   
123,897
   
126,555
   
*
 
Daryl B. Winter, Ph.D.(2)
   
73,185
   
87,278
   
160,463
   
*
 
James W. Young, Ph.D.(3)
   
248,631
   
140,367
   
388,998
   
1.3
 
Directors, not including CEO and Executive Chairman:
                         
Anthony B. Evnin, Ph.D.(4)
   
1,141,744
   
7,500
   
1,149,244
   
3.9
 
Stephen P.A. Fodor, Ph.D.
   
_
   
41,030
   
41,030
   
*
 
Matthew K. Fust
   
_
   
33,088
   
33,088
   
*
 
Steven D. Goldby
   
_
   
41,030
   
41,030
   
*
 
Jonathan S. Leff
   
3,626,879(5
)
 
249,046(6
)
 
3,875,925
   
13.0
 
Homer L. Pearce, Ph.D.
   
_
   
_
   
_
   
*
 
David C. Stump, M.D.
   
_
   
_
   
_
   
*
 
James A. Wells, Ph.D.(7)
   
320,882
   
153,383
   
474,265
   
1.6
 
All directors and executive officers as a group
(13 persons)
   
5,448,871
   
1,358,406
   
6,807,277
   
22.1
%
5% Stockholders
                         
Entities affiliated with Alta Partners
   
1,932,464(8
)
 
579,739(9
)
 
2,512,203
   
8.4
%
Biogen Idec(10)
   
2,912,022
   
_
   
2,912,022
   
9.9
 
Entities affiliated with Credit Suisse First Boston(11)
   
3,406,490
   
_
   
3,406,490
   
11.6
 
Entities affiliated with Deerfield
   
1,744,006(12
)
 
483,092(13
)
 
2,227,098
   
7.4
 
Entities affiliated with Warburg Pincus
   
3,626,875(5
)
 
241,546(6
)
 
3,868,421
   
13.0
 
FMR Corporation (Fidelity Management & Research Corp.)
   
1,790,000
   
_
   
1,790,000
   
6.1
%
 


*
Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
 
(1)
This table is based upon information provided to us by our executive officers and directors and upon information about principal stockholders known to us based on Schedules 13G and 13D filed with the SEC. Unless otherwise indicated in the relevant footnote to this table and subject to community property laws where applicable, we believe that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages of beneficial ownerships are based on 29,453,510 shares of our common stock outstanding as of February 9, 2007, adjusted as required by SEC’s rules. Includes shares of common stock subject to a right of repurchase within 60 days of February 9, 2007 in the event the holder ceases to provide services to us.
 
(2)
On April 17, 2007, Dr. Winter tendered his resignation, effective as of May 17, 2007, as Senior Vice President of Intellectual Property of our company.
 
(3)
Includes 11,765 shares held by family members. Dr. Young disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
 
(4)
Includes (i) 467,380 shares held by Venrock Associates, (ii) 649,955 shares held by Venrock Associates II, L.P., and (iii) 24,409 shares held by Venrock Entrepreneur’s Fund, L.P. Anthony B. Evnin, Michael C. Brooks, Eric S. Copeland, Bryan E. Roberts, Ray A. Rothrock, Michael F. Tyrrell and Anthony Sun are the general partners of Venrock Associates and Venrock Associates II, L.P. These individuals may be deemed to share dispositive and voting power over the shares which are, or may be, deemed to be beneficially owned by Venrock Associates and Venrock Associates II, L.P. Each of these individuals disclaims beneficial ownership of these shares, except to the extent of his or her pecuniary interest therein. The general partner of Venrock Entrepreneurs Fund, L.P. is Venrock Management LLC. Anthony B. Evnin, Michael C. Brooks, Eric S. Copeland, Bryan E. Roberts, Ray A. Rothrock, Michael F. Tyrrell and Anthony Sun are the members of Venrock Management LLC. These individuals may be deemed to share dispositive and voting power over the shares which are, or may be, deemed to be beneficially owned by Venrock Entrepreneurs Fund, L.P. Each of these individuals disclaims beneficial ownership of these shares, except to the extent of his or her pecuniary interest therein. The address of Venrock Associates and its affiliates is 30 Rockefeller Plaza, Room 5508, New York, New York 10112.
 
(5)
Includes (i) 3,506,739 shares held by Warburg, Pincus Equity Partners, L.P., (ii) 109,214 shares held by Warburg, Pincus Netherlands Equity Partners I, C.V., (iii) 10,922 shares held by Warburg, Pincus Netherlands Equity Partners III, C.V., and (iv) for Mr. Leff only, 4 shares held by his family members. Warburg Pincus Partners, LLC, a subsidiary of Warburg Pincus & Co., is the sole general partner of WPEP, WP Netherlands I and WP Netherlands III. Warburg Pincus LLC manages WPEP, WP Netherlands I and WP Netherlands III. Mr. Leff, one of our directors, is a Partner of Warburg, Pincus & Co. and a Managing Director and Member of Warburg Pincus LLC. Charles R. Kaye and Joseph P. Landy are Managing General Partners of Warburg Pincus & Co. and Managing Members and Co-Presidents of Warburg Pincus LLC. Messrs. Kay, Landy and Leff may be deemed to have an indirect pecuniary interest in an indeterminate portion of the shares held by the Warburg Pincus entities. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The address of Warburg Pincus and its affiliates is 466 Lexington Avenue, New York, New York 10017.
 
(6)
Includes (i)  228,261 shares issuable upon exercise of warrants held by Warburg, Pincus Equity Partners, L.P., (ii)  12,077 shares issuable upon exercise of warrants held by Warburg, Pincus Netherlands Equity Partners I, C.V., (iii)  1,208 shares issuable upon exercise of warrants held by Warburg, Pincus Netherlands Equity Partners III, C.V., and (iv) for Mr. Leff only, an option to purchase 7,500 shares of our common stock. All such warrants are immediately exercisable. Warburg Pincus Partners, LLC, a subsidiary of Warburg Pincus & Co., is the sole general partner of WPEP, WP Netherlands I and WP Netherlands III. Warburg Pincus LLC manages WPEP, WP Netherlands I and WP Netherlands III. Mr. Leff, one of our directors, is a Partner of Warburg, Pincus & Co. and a Managing Director and Member of Warburg Pincus LLC. Charles R. Kaye and Joseph P. Landy are Managing General Partners of Warburg Pincus & Co. and Managing Members and Co-Presidents of Warburg Pincus LLC. Messrs. Kay, Landy and Leff may be deemed to have an indirect pecuniary interest in an indeterminate portion of the shares held by the Warburg Pincus entities. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The address of Warburg Pincus and its affiliates is 466 Lexington Avenue, New York, New York 10017.
 

 
(7)
Includes 2,352 shares held by a family member.
 
(8)
Includes (i) 118,870 shares held by Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, (ii) 1,769,975 shares held by Alta BioPharma Partners III, L.P., and (iii) 43,619 shares held by Alta Embarcadero BioPharma Partners III, LLC. Alta Partners III, Inc. provides investment advisory services to Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, Alta BioPharma Partners III, L.P. and Alta Embarcadero BioPharma Partners III, LLC, which we refer to collectively as the Alta Funds. The managing directors of Alta BioPharma Management III, LLC, which is a general partner of Alta BioPharma Partners III, L.P. and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, and the managers of Alta Embarcadero BioPharma Partners III, LLC exercise sole dispositive and voting power over the shares owned by the Alta Funds. Certain principals of Alta Partners III, Inc., Jean Deleage, Alix Marduel, Farah Campsi, Edward Penhoet and Ed Hurwitz, are managing directors of Alta BioPharma Management III, LLC and managers of Alta Embarcadero BioPharma Partners III, LLC. These individuals may be deemed to share dispositive and voting power over the shares held by the Alta Funds. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein. The address of Alta Partners III, Inc. and its affiliates is One Embarcadero Center, 37th Floor, San Francisco, California 94111.
 
(9)
Includes (i) 35,661 shares issuable upon exercise of warrants held by Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, (ii)  530,992 shares issuable upon exercise of warrants held by Alta BioPharma Partners III, L.P., and (iii) 13,086 shares issuable upon exercise of warrants held by Alta Embarcadero BioPharma Partners III, LLC. All such warrants are immediately exercisable. Alta Partners III, Inc. provides investment advisory services to Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, Alta BioPharma Partners III, L.P. and Alta Embarcadero BioPharma Partners III, LLC, which we refer to collectively as the Alta Funds. The managing directors of Alta BioPharma Management III, LLC, which is a general partner of Alta BioPharma Partners III, L.P. and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, and the managers of Alta Embarcadero BioPharma Partners III, LLC exercise sole dispositive and voting power over the shares owned by the Alta Funds. Certain principals of Alta Partners III, Inc., Jean Deleage, Alix Marduel, Farah Campsi, Edward Penhoet and Ed Hurwitz, are managing directors of Alta BioPharma Management III, LLC and managers of Alta Embarcadero BioPharma Partners III, LLC. These individuals may be deemed to share dispositive and voting power over the shares held by the Alta Funds. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein. The address of Alta Partners III, Inc. and its affiliates is One Embarcadero Center, 37th Floor, San Francisco, California 94111.
 
(10)
Biogen Idec MA, Inc., a Massachusetts corporation, is a wholly-owned subsidiary of Biogen Idec Inc., a Delaware corporation that is publicly traded on the Nasdaq National Market. James C. Mullen, Bruce R. Ross and Peter N. Kellogg are the directors and executive officers of Biogen Idec MA, Inc. These individuals may be deemed to share dispositive and voting power over the shares which are, or may be, deemed to be beneficially owned by Biogen Idec MA, Inc. Each of these individuals disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
 
(11)
Includes (i) 175,775 shares held by EMA Partners Fund 2000, L.P., or EMA Partners, (ii) 233,004 shares held by EMA Private Equity Fund 2000, L.P., or EMA Private, (iii) 654,387 shares held by Credit Suisse First Boston Equity Partners (Bermuda), L.P., or CSFB Bermuda, (iv) 2,341,061 shares held by Credit Suisse First Boston Equity Partners, L.P., or CSFB-EP, and (v) 2,263 shares held by Credit Suisse First Boston U.S. Executive Advisors, L.P., or CSFB U.S. Credit Suisse First Boston Advisory Partners, LLC, or CSFB Advisory, manages the investments of CSFB-EP, CSFB Bermuda and CSFB U.S. EMA Partners and EMA Private each must invest in and dispose of its portfolio securities simultaneously with CSFB-EP on a pro-rata basis. CFSB Advisory may be deemed to have dispositive and voting power over the shares held by CSFB-EP, CSFB Bermuda, CSFB U.S., EMA Partners and EMA Private. Credit Suisse Group, through a wholly-owned subsidiary, is a parent of CSFB Advisory, and may be deemed to have dispositive and voting power over the shares held by CSFB-EP, CSFB Bermuda, CSFB U.S., EMA Partners and EMA Private. Credit Suisse Group disclaims beneficial ownership of the shares owned by such investment partnerships. The address of Credit Suisse First Boston and its affiliates is Eleven Madison Avenue, New York, New York 10010.
 

 
(12)
Includes (i) 435,000 shares held by Deerfield International Limited, (ii) 323,306 shares held by Deerfield Partners, L.P., (iii) 642,385 shares held by Deerfield Special Situations Fund International, Ltd.,   and (iv) 343,315 shares held by Deerfield Special Situations Fund, L.P. James Flynn, investment manager of each of Deerfield International Limited, Deerfield Partners, L.P., Deerfield Special Situations Fund International, Ltd. and Deerfield Special Situations Fund, L.P. has dispositive and voting power over the shares owned by these funds. The address of Deerfield and its affiliates is 780 Third Avenue, 37th Floor, New York, New York 10017.
 
(13)
Includes (i) 127,000 shares issuable upon exercise of warrants held by Deerfield International Limited, (ii)  99,092 shares issuable upon exercise of warrants held by Deerfield Partners, L.P., (iii) 167,000 shares issuable upon exercise of warrants held by Deerfield Special Situations Fund International, Ltd.,   and (iv) 90,000 shares issuable upon exercise of warrants held by Deerfield Special Situations Fund, L.P. All such warrants are immediately exercisable.  James Flynn, investment manager of each of Deerfield International Limited, Deerfield Partners, L.P., Deerfield Special Situations Fund International, Ltd. and Deerfield Special Situations Fund, L.P. has dispositive and voting power over the shares owned by these funds.  The address of Deerfield and its affiliates is 780 Third Avenue, 37th Floor, New York, New York 10017.
 
Equity Compensation Plan Information

The following table provides information regarding our equity compensation plans as of December 31, 2006.
 
 
 
(A)
 
(B)
 
(C)
 
Plan Category
 
Number of Securities
to be Issued
upon Exercise of
Outstanding Options
and Rights
 
Weighted Average
Exercise Price of
Outstanding Options
 and Rights
 
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
(Excluding Securities
Reflected in Column A)
 
Equity Compensation Plans Approved by Stockholders(1)
   
3,822,435(2
)
$
4.26
   
561,581(3
)
Equity Compensation Plans Not Approved by Stockholders(4)
   
120,000
 
$
5.71
   
80,000
 
Total
   
3,942,435
 
$
4.30
   
641,581
 

 
(1)
Includes our 1998 Stock Plan, or 1998 Plan, 2001 Stock Plan, or 2001 Plan, 2005 Equity Incentive Award Plan, or 2005 Plan, and Employee Stock Purchase Plan, or ESPP.
 
(2)
Includes (i) 1,310,370 shares of common stock issuable upon the exercise of options granted under our 1998 Plan, all of which were exercisable as of December 31, 2006, (ii) 229,969 shares of common stock issuable upon the exercise of options granted under our 2001 Plan, all of which were exercisable as of December 31, 2006, and (iii) 2,282,096 shares of common stock issuable upon the exercise of options granted under our 2005 Plan, 403,282 of which were exercisable as of December 31, 2006. Excludes purchase rights currently accruing under the ESPP. Offering periods under the ESPP are 12-month periods, which are comprised of two six-month purchase periods. Eligible employees may purchase shares of common stock at a price equal to 85% of the lower of the fair market value of the common stock at the beginning of each offering period or the end of each semi-annual purchase period. Participation is limited to 20% of an employee’s eligible compensation, subject to limitations under the Code.
 
(3)
Includes (i) 396,716 shares of common stock available for issuance under our 2005 Plan and (ii) 164,865 shares of common stock available for issuance under our ESPP. 202,941 shares of our common stock were initially reserved for issuance under our ESPP. The number of shares of common stock reserved under our ESPP will automatically increase on the first trading day each year, beginning in 2006, by an amount equal to the least of:  (i) 0.5% of our outstanding shares of common stock outstanding on such date, (ii) 135,294 shares or (iii) a lesser amount determined by our Board of Directors. The maximum aggregate number of shares which may be issued over the term of the ESPP is 1,352,941 shares.
 

 
(4)
Our 2006 Employment Commencement Incentive Plan, or 2006 Plan, became effective on January 1, 2006. Effective January 1, 2007, our Board of Directors increased the 2006 Plan by an additional 200,000 shares such that the aggregate number of shares of our common stock reserved for issuance under our 2006 Plan, which did not require stockholder approval pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), is 400,000 shares.
 
The additional information required by this Item 12 concerning our equity compensation plans is discussed in Note 11 to the financial statements contained in Part II, Item 8 of this report. The Equity Compensation Plan Information above supercedes in its entirety the section entitled “ Securities Authorized For Issuance Under Equity Compensation Plans as of December 31, 2006 ,” which previously appeared in Part II, Item 5 of this Annual Report on this Form 10-K for the year ended December 31, 2006.
 

 
PART IV
 
ITEM 15.          EXHIBIT, FINANCIAL STATEMENT SCHEDULES
 
(a)           Exhibits and Financial Statement Schedules:
 
(1)           Financial Statements
 
See the “Index to Financial Statements” in Part II Item 8 of this report.
 
(2)           Financial Statement Schedules
 
All financial statement schedules are omitted because they are not applicable, or the information is included in the financial statements or notes thereto.
 
(3)           Exhibits
 
A list of exhibits filed with this Form 10-K or incorporated by reference is found in the Exhibit Index immediately following signature page of this report.
 
(b)          Exhibits:
 
See Item 15(a)(3) above.
 
(c)           Financial Schedules:
 
See Item 15(a)(2) above.
 

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Sunesis Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May 23, 2007.
 
 
 
SUNESIS PHARMACEUTICALS, INC.
 
 
 
By:
 
 
 
/s/  ERIC H. BJERKHOLT
 
 
 
 
Eric H. Bjerkholt
 
 
 
 
Senior Vice President, Corporate Development
 
 
 
 
and Finance, Chief Financial Officer
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Signature
 
 
 
Title
 
 
 
Date
 
 
/s/  JAMES W. YOUNG, PH.D.
 
 
 
Executive Chairman of the Board
 
 
 
May 23, 2007
James W. Young, Ph.D.
 
 
 
 
 
/s/  DANIEL N. SWISHER, JR.
 
 
 
President, Chief Executive Officer and
 
 
 
May 23, 2007
Daniel N. Swisher, Jr.
 
Director (Principal Executive Officer)
 
 
 
/s/  ERIC H. BJERKHOLT
 
 
 
Senior Vice President, Corporate Development
 
 
 
May 23, 2007
Eric H. Bjerkholt
 
and Finance, Chief Financial Officer
 
 
 
 
(Principal Financial Officer
 
 
 
 
and Principal Accounting Officer)
 
 
 
/s/  ANTHONY B. EVNIN, PH.D.
 
 
 
Director
 
 
 
May 23, 2007
Anthony B. Evnin, Ph.D.
 
 
 
 
 
/s/  STEPHEN P.A. FODOR, PH.D.
 
 
 
Director
 
 
 
May 23, 2007
Stephen P.A. Fodor, Ph.D.
 
 
 
 
 
/s/  MATTHEW K. FUST
 
 
 
Director
 
 
 
May 23, 2007
Matthew K. Fust
 
 
 
 
 
/s/  STEVEN D. GOLDBY
 
 
 
Director
 
 
 
May 23, 2007
Steven D. Goldby
 
 
 
 
 
/s/ JONATHAN S. LEFF
 
 
 
Director
 
 
 
May 23, 2007
Jonathan S. Leff
 
 
 
 
 
/s/  HOMER L. PEARCE, PH.D.
 
 
 
Director
 
 
 
May 23, 2007
Homer L. Pearce
 
 
 
 
 
/s/  DAVID C. STUMP, M.D.
 
 
 
Director
 
 
 
May 23, 2007
David C. Stump, M.D.
 
 
 
 
 
/s/ JAMES A. WELLS, PH.D.
 
 
 
Director
 
 
 
May 23, 2007
James A. Wells, Ph.D.
 
 
       


EXHIBIT INDEX
 
Exhibit
Number
 
Description
3.1**
 
Amended and Restated Certificate of Incorporation of the Registrant.
3.2**
 
Amended and Restated Bylaws of the Registrant.
10.48*             
 
S
Summary of Non-Employee Director Compensation.
10.49*             
 
Named Executive Officer Compensation and Bonus Program.
31.1
 
Certification of Chief Executive Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
31.2
 
Certification of Chief Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.

*
This exhibit is a management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item 15(b) of Form 10-K.
 
**
Exhibits 3.1 and 3.2 hereto update Exhibits 3.1 and 3.2 of the Company’s Form S-3 (Registration Statement No. 333-138736) and are incorporated by reference therein.
 


AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
SUNESIS PHARMACEUTICALS, INC.
 
Daniel N. Swisher, Jr. and Daryl B. Winter, hereby certify that:
 
ONE:   The original name of this company was Mosaic Pharmaceuticals, Inc., and the date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was February 10, 1998.
 
TWO:   They are the Chief Executive Officer and the Secretary, respectively, of Sunesis Pharmaceuticals, Inc., a Delaware corporation.
 
THREE:   The Certificate of Incorporation of this Corporation is hereby amended and restated to read as follows:
 
ARTICLE I
 
The name of the corporation is Sunesis Pharmaceuticals, Inc. (the “ Corporation ”).
 
ARTICLE II
 
The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Zip Code 19801. The name of the registered agent at such address is The Corporation Trust Company.
 
ARTICLE III
 
The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.
 
ARTICLE IV
 
A.   This Corporation is authorized to issue two classes of stock to be designated, respectively, “ Common Stock ” and “ Preferred Stock .” The total number of shares that the Corporation is authorized to issue is one hundred five million (105,000,000) shares, one hundred million (100,000,000) shares of which shall be Common Stock and five million (5,000,000) shares of which shall be Preferred Stock. The Common Stock shall have a par value of $0.0001 per share and the Preferred Stock shall have a par value of $0.0001 per share.
 
B.   The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation (the “ Board of Directors ”) is hereby authorized, by filing a certificate (a “ Certificate of Designation ”) pursuant to the Delaware General Corporation Law, to fix or alter from time to time the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions of any wholly unissued series of Preferred Stock; and to establish from time to time the number of shares constituting any such series or any of them; and to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
 
 
 

 
 
ARTICLE V
 
For the management of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation and regulation of the powers of the Corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:
 
A.     (1)   The management of the business and the conduct of the affairs of the Corporation shall be vested in the Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the Board of Directors.
 
(2)   Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, following the date on which the Corporation is no longer subject to Section 2115 of the California Corporations Code (the “ Qualifying Record Date ”), the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the Qualifying Record Date, the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders, following the Qualifying Record Date, the term of office of the Class II directors shall expire and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the Qualifying Record Date, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.
 
Notwithstanding the foregoing provisions of this Article V(A), each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.
 
(3)   Subject to the rights of the holders of any series of Preferred Stock, the Board of Directors or any individual director may be removed from office at any time (i) with cause by the affirmative vote of the holders of a majority of the voting power of all the then outstanding shares of voting stock of the Corporation, entitled to vote at an election of directors (the “ Voting Stock ”) or (ii) without cause by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3 %) of the voting power of all the then-outstanding shares of the Voting Stock.
 
 
-2-

 
 
(4)   Subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified.
 
B.       (1)   Subject to Article IX of the Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter or repeal Bylaws of the Corporation. Notwithstanding the foregoing, the Bylaws of the Corporation may be rescinded, altered, amended or repealed in any respect by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3 %) of the voting power of all the then-outstanding shares of the Voting Stock.
 
(2)   The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.
 
(3)   No action shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders called in accordance with the Bylaws, and following the Qualifying Record Date, no action shall be taken by the stockholders by written consent.
 
(4)   Special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption) or (iv) by the holders of the shares entitled to cast not less than ten percent (10%) of the votes at the meeting, and shall be held at such place, on such date, and at such time as the Board of Directors shall fix.
 
(5)   Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.
 
ARTICLE VI
 
A.   To the maximum extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.
 
 
-3-

 
 
B.   The Corporation shall indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director or officer of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director or officer at the request of the Corporation or any predecessor to the Corporation.
 
C.   Neither any amendment nor repeal of this Article VI, nor the adoption of any provision of the Corporation’s certificate of incorporation inconsistent with this Article VI, shall eliminate or reduce the effect of this Article VI in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article VI, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.
 
ARTICLE VII
 
Notwithstanding any other provisions of this Amended and Restated Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Voting Stock required by law, this Amended and Restated Certificate of Incorporation or any Certificate of Designation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the Voting Stock, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI and VII.
 
* * * *
 
FOUR:   This Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors.
 
FIVE:   This Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the Delaware General Corporation Law by the Board of Directors and the stockholders of the Corporation. A majority of the outstanding stock entitled to vote or act by written consent and a majority of the outstanding stock of each class entitled to vote or act by written consent as a class approved this Amended and Restated Certificate of Incorporation by written consent in accordance with Section 228 of the Delaware General Corporation Law and written notice of such was given by the Corporation in accordance with said Section 228.
 
 
-4-

 


IN WITNESS WHEREOF , the undersigned have executed this Amended and Restated Certificate of Incorporation on this 14th day of September, 2005.
 

 
By:   /s/ Daniel N. Swisher, Jr.                           
       Daniel N. Swisher, Jr.
       President and Chief Executive Officer
 

 
By:   /s/ Daryl B. Winter, Ph.D.                         
       Daryl B. Winter, Ph.D.
       Secretary
 
 
 
 

 

 
AMENDED AND RESTATED B YLAWS OF
 
SUNESIS PHARMACEUTICALS, INC.
 
(a Delaware corporation)
 





TABLE OF CONTENTS
 
 
Page
ARTICLE I - CORPORATE OFFICES
1
1.1
  REGISTERED OFFICE
1
1.2
  OTHER OFFICES
1
ARTICLE II - MEETINGS OF STOCKHOLDERS
1
2.1
  PLACE OF MEETINGS
1
2.2
  ANNUAL MEETING
1
2.3
  SPECIAL MEETING
1
2.4
  ADVANCE NOTICE PROCEDURES; NOTICE OF STOCKHOLDERS’ MEETINGS
2
2.5
  MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE
3
2.6
  QUORUM
3
2.7
  ADJOURNED MEETING; NOTICE
4
2.8
  CONDUCT OF BUSINESS
4
2.9
  VOTING
4
2.10
  STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A   MEETING
4
2.11
  RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING   CONSENTS
4
2.12
  PROXIES
5
2.13
  LIST OF STOCKHOLDERS ENTITLED TO VOTE
5
2.14
  INSPECTORS OF ELECTION
5
ARTICLE III - DIRECTORS
6
3.1
  POWERS
6
3.2
  NUMBER OF DIRECTORS
6
3.3
  ELECTION, QUALIFICATION AND TERM OF OFFICE OF   DIRECTORS
6
3.4
  RESIGNATION AND VACANCIES
7
3.5
  PLACE OF MEETINGS; MEETINGS BY TELEPHONE
7
3.6
  REGULAR MEETINGS
8
3.7
  SPECIAL MEETINGS; NOTICE
8
3.8
  QUORUM
8
3.9
BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING
8
3.10
  FEES AND COMPENSATION OF DIRECTORS
9
3.11
  REMOVAL OF DIRECTORS
9
ARTICLE IV - COMMITTEES
9
4.1
  COMMITTEES OF DIRECTORS
9
4.2
  COMMITTEE MINUTES
9
4.3
  MEETINGS AND ACTION OF COMMITTEES
9
ARTICLE V - OFFICERS
10
5.1
  OFFICERS
10
5.2
  APPOINTMENT OF OFFICERS
10
 
-i-

 
  TABLE OF CONTENTS
(continued)
 
   
Page
5.3
  SUBORDINATE OFFICERS
10
5.4
  REMOVAL AND RESIGNATION OF OFFICERS
11
5.5
  VACANCIES IN OFFICES
11
5.6
REPRESENTATION OF SHARES OF OTHER CORPORATIONS
11
5.7
  AUTHORITY AND DUTIES OF OFFICERS
11
ARTICLE VI - RECORDS AND REPORTS
11
6.1
  MAINTENANCE AND INSPECTION OF RECORDS
11
6.2
  INSPECTION BY DIRECTORS
12
ARTICLE VII - GENERAL MATTERS
12
7.1
EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS
12
7.2
  STOCK CERTIFICATES; PARTLY PAID SHARES
12
7.3
  SPECIAL DESIGNATION ON CERTIFICATES
13
7.4
  LOST CERTIFICATES
13
7.5
  CONSTRUCTION; DEFINITIONS
13
7.6
  DIVIDENDS
13
7.7
  FISCAL YEAR
13
7.8
  SEAL
14
7.9
  TRANSFER OF STOCK
14
7.10
  STOCK TRANSFER AGREEMENTS
14
7.11
  REGISTERED STOCKHOLDERS
14
7.12
  WAIVER OF NOTICE
14
ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION
15
8.1
  NOTICE BY ELECTRONIC TRANSMISSION
15
8.2
  DEFINITION OF ELECTRONIC TRANSMISSION
15
8.3
  INAPPLICABILITY
16
ARTICLE IX - INDEMNIFICATION
16
9.1
  INDEMNIFICATION OF DIRECTORS AND OFFICERS
16
9.2
  INDEMNIFICATION OF OTHERS
16
9.3
  PREPAYMENT OF EXPENSES
16
9.4
  DETERMINATION; CLAIM
16
9.5
  NON-EXCLUSIVITY OF RIGHTS
17
9.6
  INSURANCE
17
9.7
  OTHER INDEMNIFICATION
17
9.8
  AMENDMENT OR REPEAL
17
ARTICLE X - AMENDMENTS
17

-ii-



AMENDED AND RESTATED
BYLAWS OF SUNESIS PHARMACEUTICALS, INC.
 


 
ARTICLE I -  CORPORATE OFFICES
 
1.1    REGISTERED OFFICE .
 
The registered office of Sunesis Pharmaceuticals, Inc. shall be fixed in the corporation’s certificate of incorporation, as the same may be amended from time to time.
 
1.2    OTHER OFFICES .
 
The corporation’s Board of directors (the “ Board ”) may at any time establish other offices at any place or places where the corporation is qualified to do business.
 
ARTICLE II -  MEETINGS OF STOCKHOLDERS
 
2.1    PLACE OF MEETINGS .
 
Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the Board. The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section  211(a)(2) of the Delaware General Corporation Law (the “ DGCL ”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the corporation’s principal executive office.
 
2.2    ANNUAL MEETING .
 
The annual meeting of stockholders shall be held each year. The Board shall designate the date and time of the annual meeting. In the absence of such designation the annual meeting of stockholders shall be held on the second Tuesday of May of each year at 10:00 a.m. However, if such day falls on a legal holiday, then the meeting shall be held at the same time and place on the next succeeding business day. At the annual meeting, directors shall be elected and any other proper business may be transacted.
 
2.3    SPECIAL MEETING .
 
A special meeting of the stockholders may be called at any time by the Board, chairperson of the Board, chief executive officer or president (in the absence of a chief executive officer), but such special meetings may not be called by any other person or persons.
 
No business may be transacted at such special meeting other than the business specified in such notice to stockholders. Nothing contained in this paragraph of this Section  2.3 shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board may be held.
 

 
2.4    ADVANCE NOTICE PROCEDURES; NOTICE OF STOCKHOLDERS’ MEETINGS .
 
(i)    At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the board of directors, (B) otherwise properly brought before the meeting by or at the direction of the board of directors, or (C) otherwise properly brought before the meeting by a stockholder. For business to be properly brought before an annual meeting by a stockholder, the stockholder must have given timely notice thereof in writing to the secretary of the corporation. To be timely, a stockholder’s notice must be delivered to or mailed and received at the principal executive offices of the corporation not less than one hundred twenty (120) calendar days before the one year anniversary of the date on which the corporation first mailed its proxy statement to stockholders in connection with the previous year’s annual meeting of stockholders; provided , however , that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the date of the prior year’s meeting, notice by the stockholder to be timely must be so received not later than the close of business on the later of one hundred twenty (120) calendar days in advance of such annual meeting and ten (10) calendar days following the date on which public announcement of the date of the meeting is first made. A stockholder’s notice to the secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting: (a) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (b) the name and address, as they appear on the corporation’s books, of the stockholder proposing such business, (c) the class and number of shares of the corporation that are beneficially owned by the stockholder, (d) any material interest of the stockholder in such business, and (e) any other information that is required to be provided by the stockholder pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “1934 Act”), in his capacity as a proponent to a stockholder proposal. Notwithstanding the foregoing, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholder’s meeting, stockholders must provide notice as required by the regulations promulgated under the 1934 Act. Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at any annual meeting except in accordance with the procedures set forth in this paragraph (i). The chairman of the annual meeting shall, if the facts warrant, determine and declare at the meeting that business was not properly brought before the meeting and in accordance with the provisions of this paragraph (i), and, if he should so determine, he shall so declare at the meeting that any such business not properly brought before the meeting shall not be transacted.
 
(ii)    Only persons who are nominated in accordance with the procedures set forth in this paragraph (ii) shall be eligible for election as directors. Nominations of persons for election to the board of directors of the corporation may be made at a meeting of stockholders by or at the direction of the board of directors or by any stockholder of the corporation entitled to vote in the election of directors at the meeting who complies with the notice procedures set forth in this paragraph (ii). Such nominations, other than those made by or at the direction of the board of directors, shall be made pursuant to timely notice in writing to the secretary of the corporation in accordance with the provisions of paragraph (i) of this Section 2.4. Such stockholder’s notice shall set forth (a) as to each person, if any, whom the stockholder proposes to nominate for election or re-election as a director: (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (C) the class and number of shares of the corporation that are beneficially owned by such person, (D) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, and (E) any other information relating to such person that is required to be disclosed in solicitations of proxies for elections of directors, or is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including without limitation such person’s written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected); and (b) as to such stockholder giving notice, the information required to be provided pursuant to paragraph (i) of this Section 2.4. At the request of the board of directors, any person nominated by a stockholder for election as a director shall furnish to the secretary of the corporation that information required to be set forth in the stockholder’s notice of nomination which pertains to the nominee. No person shall be eligible for election as a director of the corporation unless nominated in accordance with the procedures set forth in this paragraph (ii). The chairman of the meeting shall, if the facts warrant, determine and declare at the meeting that a nomination was not made in accordance with the procedures prescribed by these bylaws, and if he should so determine, he shall so declare at the meeting, and the defective nomination shall be disregarded.
 
-2-

 
These provisions shall not prevent the consideration and approval or disapproval at an annual meeting of reports of officers, directors and committees of the board of directors, but in connection therewith no new business shall be acted upon at any such meeting unless stated, filed and received as herein provided. Notwithstanding anything in these bylaws to the contrary, no business brought before a meeting by a stockholder shall be conducted at an annual meeting except in accordance with procedures set forth in this Section 2.4.
 
All notices of meetings of stockholders shall be sent or otherwise given in accordance with either Section  2.5 or Section 8.1 of these bylaws not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.
 
2.5    MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE .
 
Notice of any meeting of stockholders shall be given:
 
(i)    if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at his or her address as it appears on the corporation’s records; or
 
(ii)    if electronically transmitted as provided in Section 8.1 of these bylaws.
 
An affidavit of the secretary or an assistant secretary of the corporation or of the transfer agent or any other agent of the corporation that the notice has been given by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
 
2.6    QUORUM .
 
The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If, however, such quorum is not present or represented at any meeting of the stockholders, then either (i) the chairperson of the meeting, or (ii) the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.
 
-3-

 
2.7    ADJOURNED MEETING; NOTICE .
 
When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place if any thereof, and the means of remote communications if any by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
 
2.8    CONDUCT OF BUSINESS .
 
The chairperson of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business.
 
2.9    VOTING .
 
The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section  2.11 of these bylaws, subject to Section  217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL.
 
Except as may be otherwise provided in the certificate of incorporation or these bylaws, each stockholder shall be entitled to one vote for each share of capital stock held by such stockholder.
 
2.10    STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING .
 
Subject to the rights of the holders of the shares of any series of Preferred Stock or any other class of stock or series thereof having a preference over the Common Stock as dividend or upon liquidation, any action required or permitted to be taken by the stockholders of the corporation must be effected at a duly called annual or special meeting of stockholders of the corporation and may not be effected by any consent in writing by such stockholders.
 
2.11    RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS
 
In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted and which shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 60 days prior to any other such action.
 
If the Board does not so fix a record date:
 
(i)    The record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.
 
-4-

 
(ii)    The record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.
 
A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however , that the Board may fix a new record date for the adjourned meeting.
 
2.12    PROXIES
 
Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL.
 
2.13    LIST OF STOCKHOLDERS ENTITLED TO VOTE
 
The officer who has charge of the stock ledger of the corporation shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the corporation’s principal executive office. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them.
 
2.14    INSPECTORS OF ELECTION
 
A written proxy may be in the form of a telegram, cablegram, or other means of electronic transmission which sets forth or is submitted with information from which it can be determined that the telegram, cablegram, or other means of electronic transmission was authorized by the person.
 
Before any meeting of stockholders, the board of directors shall appoint an inspector or inspectors of election to act at the meeting or its adjournment. The number of inspectors shall be either one (1) or three (3). If any person appointed as inspector fails to appear or fails or refuses to act, then the chairperson of the meeting may, and upon the request of any stockholder or a stockholder's proxy shall, appoint a person to fill that vacancy.
 
-5-

 
Such inspectors shall:
 
(i)    determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence of a quorum, and the authenticity, validity, and effect of proxies;
 
(ii)    receive votes, ballots or consents;
 
(iii)    hear and determine all challenges and questions in any way arising in connection with the right to vote;
 
(iv)    count and tabulate all votes or consents;
 
(v)    determine when the polls shall close;
 
(vi)    determine the result; and
 
(vii)    do any other acts that may be proper to conduct the election or vote with fairness to all stockholders.
 
The inspectors of election shall perform their duties impartially, in good faith, to the best of their ability and as expeditiously as is practical. If there are three (3) inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. Any report or certificate made by the inspectors of election is prima facie evidence of the facts stated therein.
 
ARTICLE III -  DIRECTORS
 
3.1    POWERS
 
Subject to the provisions of the DGCL and any limitations in the certificate of incorporation or these bylaws relating to action required to be approved by the stockholders or by the outstanding shares, the business and affairs of the corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board.
 
3.2    NUMBER OF DIRECTORS
 
The authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall consist of at least one member. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires.
 
3.3    ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS
 
Except as provided in Section  3.4 of these bylaws, each director, including a director elected to fill a vacancy, shall hold office until the expiration of the term for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. Directors need not be stockholders unless so required by the certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors.
 
-6-

 
If so provided in the certificate of incorporation, the directors of the corporation shall be divided into three classes.
 
3.4    RESIGNATION AND VACANCIES
 
Any director may resign at any time upon notice given in writing or by electronic transmission to the corporation. When one or more directors so resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this section in the filling of other vacancies.
 
Unless otherwise provided in the certificate of incorporation or these bylaws, vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. If the directors are divided into classes, a person so elected by the directors then in office to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall have been duly elected and qualified.
 
If at any time, by reason of death or resignation or other cause, the corporation should have no directors in office, then any officer or any stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special meeting of stockholders in accordance with the provisions of the certificate of incorporation or these bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section  211 of the DGCL.
 
If, at the time of filling any vacancy or any newly created directorship, the directors then in office constitute less than a majority of the whole Board (as constituted immediately prior to any such increase), then the Court of Chancery may, upon application of any stockholder or stockholders holding at least 10% of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office as aforesaid, which election shall be governed by the provisions of Section  211 of the DGCL as far as applicable.
 
3.5    PLACE OF MEETINGS; MEETINGS BY TELEPHONE
 
The Board may hold meetings, both regular and special, either within or outside the State of Delaware.
 
Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.
 
-7-

 
3.6    REGULAR MEETINGS
 
Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board.
 
3.7    SPECIAL MEETINGS; NOTICE
 
Special meetings of the Board for any purpose or purposes may be called at any time by the chairperson of the Board, the chief executive officer, the president, the secretary or a majority of the authorized number of directors.
 
Notice of the time and place of special meetings shall be:
 
(i)    delivered personally by hand, by courier or by telephone;
 
(ii)    sent by United States first-class mail, postage prepaid;
 
(iii)    sent by facsimile; or
 
(iv)    sent by electronic mail,
 
directed to each director at that director’s address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the corporation’s records.
 
If the notice is (i) delivered personally by hand, by courier or by telephone, (ii) sent by facsimile or (iii) sent by electronic mail, it shall be delivered or sent at least 24 hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting. Any oral notice may be communicated to the director. The notice need not specify the place of the meeting (if the meeting is to be held at the corporation’s principal executive office) nor the purpose of the meeting.
 
3.8    QUORUM
 
At all meetings of the Board, a majority of the authorized number of directors shall constitute a quorum for the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.
 
A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority of the required quorum for that meeting.
 
3.9    BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING
 
Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.
 
-8-

 
3.10    FEES AND COMPENSATION OF DIRECTORS
 
Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board shall have the authority to fix the compensation of directors.
 
3.11    REMOVAL OF DIRECTORS
 
Any director may be removed from office by the stockholders of the corporation only for cause.
 
No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director’s term of office.
 
ARTICLE IV -  COMMITTEES
 
4.1    COMMITTEES OF DIRECTORS
 
The Board may, by resolution passed by a majority of the authorized number of directors, designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaw of the corporation,
 
4.2    COMMITTEE MINUTES
 
Each committee shall keep regular minutes of its meetings and report the same to the Board when required.
 
4.3    MEETINGS AND ACTION OF COMMITTEES
 
Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:
 
(i)    Section  3.5 (place of meetings and meetings by telephone);
 
-9-

 
(ii)    Section  3.6 (regular meetings);
 
(iii)    Section  3.7 (special meetings and notice);
 
(iv)    Section  3.8 (quorum);
 
(v)    Section 7.12 (waiver of notice); and
 
(vi)    Section  3.9 (action without a meeting)
 
with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members. However :
 
(i)    the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;
 
(ii)    special meetings of committees may also be called by resolution of the Board; and
 
(iii)    notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws.
 
ARTICLE V -  OFFICERS
 
5.1    OFFICERS
 
The officers of the corporation shall be a president and a secretary. The corporation may also have, at the discretion of the Board, a chairperson of the Board, a vice chairperson of the Board, a chief executive officer, a chief financial officer or treasurer, one or more vice presidents, one or more assistant vice presidents, one or more assistant treasurers, one or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person.
 
5.2    APPOINTMENT OF OFFICERS
 
The Board shall appoint the officers of the corporation, except such officers as may be appointed in accordance with the provisions of Sections  5.3 and 5.5 of these bylaws, subject to the rights, if any, of an officer under any contract of employment.
 
5.3    SUBORDINATE OFFICERS
 
The Board may appoint, or empower the chief executive officer or, in the absence of a chief executive officer, the president, to appoint, such other officers and agents as the business of the corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to time determine.
 
-10-

 
5.4    REMOVAL AND RESIGNATION OF OFFICERS
 
Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board at any regular or special meeting of the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.
 
Any officer may resign at any time by giving written notice to the corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the corporation under any contract to which the officer is a party.
 
5.5    VACANCIES IN OFFICES
 
Any vacancy occurring in any office of the corporation shall be filled by the Board or as provided in Section 5.2 .
 
5.6    REPRESENTATION OF SHARES OF OTHER CORPORATIONS
 
The chairperson of the Board, the president, any vice president, the treasurer, the secretary or assistant secretary of this corporation, or any other person authorized by the Board or the president or a vice president, is authorized to vote, represent, and exercise on behalf of this corporation all rights incident to any and all shares of any other corporation or corporations standing in the name of this corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.
 
5.7    AUTHORITY AND DUTIES OF OFFICERS
 
All officers of the corporation shall respectively have such authority and perform such duties in the management of the business of the corporation as may be designated from time to time by the Board or the stockholders and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.
 
ARTICLE VI -  RECORDS AND REPORTS
 
6.1    MAINTENANCE AND INSPECTION OF RECORDS
 
The corporation shall, either at its principal executive office or at such place or places as designated by the Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books, and other records.
 
Any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose the corporation’s stock ledger, a list of its stockholders, and its other books and records and to make copies or extracts therefrom. A proper purpose shall mean a purpose reasonably related to such person’s interest as a stockholder. In every instance where an attorney or other agent is the person who seeks the right to inspection, the demand under oath shall be accompanied by a power of attorney or such other writing that authorizes the attorney or other agent so to act on behalf of the stockholder. The demand under oath shall be directed to the corporation at its registered office in Delaware or at its principal executive office.
 
-11-

 
6.2    INSPECTION BY DIRECTORS
 
Any director shall have the right to examine the corporation’s stock ledger, a list of its stockholders, and its other books and records for a purpose reasonably related to his or her position as a director. The Court of Chancery is hereby vested with the exclusive jurisdiction to determine whether a director is entitled to the inspection sought. The Court may summarily order the corporation to permit the director to inspect any and all books and records, the stock ledger, and the stock list and to make copies or extracts therefrom. The Court may, in its discretion, prescribe any limitations or conditions with reference to the inspection, or award such other and further relief as the Court may deem just and proper.
 
ARTICLE VII -  GENERAL MATTERS
 
7.1    EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS
 
The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
 
7.2    STOCK CERTIFICATES; PARTLY PAID SHARES
 
The shares of the corporation shall be represented by certificates, provided that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the corporation. Notwithstanding the adoption of such a resolution by the Board, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the corporation by the chairperson or vice-chairperson of the Board, or the president or vice-president, and by the treasurer   or an assistant treasurer, or the secretary or an assistant secretary of such corporation representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
 
The corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, upon the books and records of the corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
 
-12-

 
7.3    SPECIAL DESIGNATION ON CERTIFICATES
 
If the corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the corporation shall issue to represent such class or series of stock; provided, however , that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the corporation shall issue to represent such class or series of stock a statement that the corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
 
7.4    LOST CERTIFICATES
 
Except as provided in this Section  7.5 , no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the corporation and cancelled at the same time. The corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.
 
7.5    CONSTRUCTION; DEFINITIONS
 
Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term “person” includes both a corporation and a natural person.
 
7.6    DIVIDENDS
 
The Board, subject to any restrictions contained in either (i) the DGCL, or (ii) the certificate of incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property, or in shares of the corporation’s capital stock.
 
The Board may set apart out of any of the funds of the corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the corporation, and meeting contingencies.
 
7.7    FISCAL YEAR
 
The fiscal year of the corporation shall be fixed by resolution of the Board and may be changed by the Board.
 
-13-

 
7.8    SEAL
 
The corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.
 
7.9    TRANSFER OF STOCK
 
Upon surrender to the corporation or the transfer agent of the corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction in its books.
 
7.10    STOCK TRANSFER AGREEMENTS
 
The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.
 
7.11    REGISTERED STOCKHOLDERS
 
The corporation:
 
(i)    shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;
 
(ii)    shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and
 
(iii)    shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
 
7.12    WAIVER OF NOTICE
 
Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the certificate of incorporation or these bylaws.
 
-14-

 
ARTICLE VIII -  NOTICE BY ELECTRONIC TRANSMISSION
 
8.1    NOTICE BY ELECTRONIC TRANSMISSION
 
Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the certificate of incorporation or these bylaws, any notice to stockholders given by the corporation under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the corporation. Any such consent shall be deemed revoked if:
 
(i)    the corporation is unable to deliver by electronic transmission two consecutive notices given by the corporation in accordance with such consent; and
 
(ii)    such inability becomes known to the secretary or an assistant secretary of the corporation or to the transfer agent, or other person responsible for the giving of notice.
 
However, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.
 
Any notice given pursuant to the preceding paragraph shall be deemed given:
 
(i)  
if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;
 
(ii)  
if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice;
 
(iii)  
if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and
 
(iv)  
if by any other form of electronic transmission, when directed to the stockholder.
 
An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
 
8.2    DEFINITION OF ELECTRONIC TRANSMISSION
 
An “electronic transmission” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.
 
-15-

 
8.3    INAPPLICABILITY
 
Notice by a form of electronic transmission shall not apply to Sections 164 , 296 , 311 , 312 or 324 of the DGCL.
 
ARTICLE IX -  INDEMNIFICATION
 
9.1    INDEMNIFICATION OF DIRECTORS AND OFFICERS
 
The corporation shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the corporation who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”) by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such Proceeding. The corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board.
 
9.2    INDEMNIFICATION OF OTHERS
 
The corporation shall have the power to indemnify and hold harmless, to the extent permitted by applicable law as it presently exists or may hereafter be amended, any employee or agent of the corporation who was or is made or is threatened to be made a party or is otherwise involved in any Proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such Proceeding.
 
9.3    PREPAYMENT OF EXPENSES
 
The corporation shall pay the expenses incurred by any officer or director of the corporation, and may pay the expenses incurred by any employee or agent of the corporation, in defending any Proceeding in advance of its final disposition; provided, however , that the payment of expenses incurred by a person in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the person to repay all amounts advanced if it should be ultimately determined that the person is not entitled to be indemnified under this Article IX or otherwise.
 
9.4    DETERMINATION; CLAIM
 
If a claim for indemnification or payment of expenses under this Article IX is not paid in full within sixty days after a written claim therefor has been received by the corporation the claimant may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such action the corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.
 
-16-

 
9.5    NON-EXCLUSIVITY OF RIGHTS
 
The rights conferred on any person by this Article IX shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the certificate of incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise.
 
9.6    INSURANCE
 
The corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such liability under the provisions of the DGCL.
 
9.7    OTHER INDEMNIFICATION
 
The corporation’s obligation, if any, to indemnify any person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or non-profit entity shall be reduced by any amount such person may collect as indemnification from such other corporation, partnership, joint venture, trust, enterprise or non-profit enterprise.
 
9.8    AMENDMENT OR REPEAL
 
Any repeal or modification of the foregoing provisions of this Article IX shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification.”
 
ARTICLE X -  AMENDMENTS
 
These bylaws may be adopted, amended or repealed by the stockholders entitled to vote. However, the corporation may, in its certificate of incorporation, confer the power to adopt, amend or repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors shall not divest the stockholders of the power, nor limit their power to adopt, amend or repeal bylaws.
 
-17-


Exhibit 10.48
Summary of Non-Employee Director Cash Compensation
 
Annual Cash Retainer:   $ 20,000  
         
Annual Committee Fee:   $ 3,000  
         
Annual Committee Chair Fee:   $ 5,000  
           
 
 

 

Exhibit 10.49

Named Executive Officer Compensation and Bonus Program

The table below sets forth the base salaries of Sunesis Pharmaceuticals, Inc.’s, or Sunesis, Named Executive Officers, as approved by the Compensation Committee of the Board of Directors of Sunesis on January 26, 2007. The Named Executive Officers were determined in reference to Sunesis’ fiscal year ended December 31, 2006. Each of the Named Executive Officers’ employment with Sunesis is on an at-will basis.


Name and Position
 
2007 Base Salary($)
 
Daniel N. Swisher, Jr
Chief Executive Officer and President
   
390,000
 
         
Eric H. Bjerkholt
Senior Vice President, Corporate Development and Finance,
Chief Financial Officer
   
285,000
 
         
Daniel C. Adelman, M.D.
Senior Vice President of Drug Discovery
   
300,000
 
         
James W. Young, Ph.D.
Executive Chairman
   
200,000
 


Each of the Named Executive Officers also participates in Sunesis’ bonus program in which the Company’s executive officers are eligible to receive an annual bonus based on a portion of their annual salary, or the Bonus Program. The Bonus Program is described more fully in Sunesis’ Proxy Statement for the 2007 Annual Meeting. Bonus targets are determined based on a review of peer group data for each Named Executive Officer’s position and level of responsibility and are reviewed annually. Actual bonus awards are determined by the Compensation Committee based on the level of achievement of corporate objectives set by the Board of Directors and individual payouts vary based on the relative contributions of the executive officers to the achievement of such objectives. For 2007, the Board of Directors has set the corporate objectives, but the Compensation Committee has not yet set the bonus targets for 2007. The Company’s other executive officers are also entitled to participate in the Bonus Program.


 
 

 

Exhibit 31.1

CERTIFICATIONS

I, Daniel N. Swisher, Jr., certify that:

1.
I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Sunesis Pharmaceuticals, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.


Date: May 23, 2007
 
 
 
/s/ Daniel N. Swisher, Jr.
 
 
Daniel N. Swisher, Jr.
 
 
Chief Executive Officer and President
 
 
 
 

 

Exhibit 31.2

CERTIFICATIONS

I, Eric H. Bjerkholt, certify that:

1.
I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Sunesis Pharmaceuticals, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.


Date: May 23, 2007
 
 
 
/s/ Eric H. Bjerkholt
 
 
Eric H. Bjerkholt
 
 
Senior Vice President, Corporate Development and
 
 
Finance, Chief Financial Officer